Prevent Alzheimer's Disease by 2020: A National Strategic Goal

Alzheimer's & dementia: the journal of the Alzheimer's Association (Impact Factor: 12.41). 04/2009; 5(2):81-4. DOI: 10.1016/j.jalz.2009.01.022
Source: PubMed
1 Follower
8 Reads
  • Source
    • ", 111th and 112th Congress). [This was an Authorization Bill; it had no impact on appropriations of funds for Alzheimer's research]. • 2008: A roadmap for the prevention of dementia – consensus recommendations of Leon Thal Symposium (LTS'07). See Khachaturian et al. Alzheimer's Dement 2008;4:156–63. • 2009: Alzheimer's Study Group (ASG), a bipartisan group of prominent, former government officials, led by Newt Gingrich and Bob Kerrey, delivered a report to the 111th Congress on March 24, 2009, calling for the creation of a National Alzheimer's Strategic Plan by 2010. On release of the report, the Alzheimer's Association pledged to seek en"
    [Show abstract] [Hide abstract]
    ABSTRACT: There exist many challenges hampering the discovery and development of effective interventions to prevent dementia. Three major trends have now intersected to influence the emerging interest in disease modifying therapies that may delay or halt dementia. The three crucial factors shaping this current focus are: 1) the emergence of the longevity revolution and the impact of a aging society, 2) the effects of the US Federal investment in research in advancing knowledge about the neurobiology of aging and dementia, and 3) the problem of US legislators and health policy makers to balance the allocation of evermore scarce research funding resources. The purpose of this essay is to provide a survey of the politics of science and to describe efforts to correctly manage the high level of expectations of both the patient and research communities. The perspective offered reviews the history and evolution of the ideas to treat or prevent dementia and Alzheimer's disease as a national strategic goal. The aim is to evaluate the interplay between science and formulation of public policy for setting research priority. We use the history of developing US National Institute of Aging's extramural research programs on brain aging and Alzheimer's disease [21-22] as an initial case study. Copyright © 2015. Published by Elsevier Ltd.
    Full-text · Article · Jun 2015 · Molecular Aspects of Medicine
  • Source
    • "Despite the availability of symptomatic pharmacotherapy (cholinesterase inhibitors, N-methyl-D-aspartate antagonists), there is currently no available intervention that unequivocally attenuates neuronal attrition and inevitable clinical deterioration in this neurodegenerative condition. Although intense efforts to develop effective neuroprotection for established disease continue to evolve, resources are being increasingly mobilized to delineate AD risk factors and implement preventive measures in a concerted effort to forestall the anticipated AD epidemic [6] [7]. 2. Apolipoprotein E: A genetic modifier of sporadic AD A companion article by Schipper, which reviewed the roles of apolipoprotein E (APOE) in the neurobiology and epidemiology of AD, was recently published in the journal Neurobiology of Aging [8], and only salient information germane to the current discussion will be recapitulated here. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Current practice guidelines advocate apolipoprotein E (APOE) genotyping in cases of dementia and mild cognitive impairment and also in asymptomatic participants within the context of clinical/epidemiological research. APOE genotyping is not recommended for prognostication in cognitively intact persons outside the research arena. On the basis of emerging developments, in this article, we revisit the notion that presymptomatic APOE testing might be medically appropriate and ethical for the purpose of Alzheimer's disease (AD) risk assessment and prevention. In support of this thesis, recent evidence is adduced indicating that (i) the potency of potentially modifiable AD determinants and responsiveness to intervention may be affected by the presence or absence of the ε4 allele, (ii) disclosure of APOE status to asymptomatic individuals seeking AD risk assessment is well tolerated when appropriate safeguards are in place, and (iii) awareness of personal AD risk in general, and APOE status in particular, may motivate individuals to engage in beneficial, risk-lowering behaviors.
    Full-text · Article · Jun 2011 · Alzheimer's & dementia: the journal of the Alzheimer's Association
  • [Show abstract] [Hide abstract]
    ABSTRACT: Low-cost and compact modules require appropriate multilayer substrates. In applications up to 24 GHz LTCC (Low Temperature Cofired Ceramics) tapes are successfully used but in the range from 60 to 110 GHz and especially in antenna design the high relative permittivity of LTCC is a strong constraint. In this paper a new progressive and inhomogeneous method of material modulation enabling radiation and optimising the radiation pattern by setting a calculated permittivity profile is presented for LTCC-multilayer antenna design. The method is applied to the design of a vivaldi antenna at 76.5 GHz integrated into a compact LTCC-multilayer near field radar sensor module [4]. By calculating the optimum permittivity profile the radiation pattern and matching have been optimised as well as the antenna size. The excellent results in the antenna design are verified and a measurement example with the radar sensor is presented.
    No preview · Conference Paper · Nov 2003
Show more